Teladoc Health (NYSE:TDOC) Upgraded to “Buy” at Bank of America

Bank of America upgraded shares of Teladoc Health (NYSE:TDOC) from a neutral rating to a buy rating in a research note issued to investors on Thursday morning, Marketbeat.com reports. The firm currently has $7.00 target price on the health services provider’s stock.

A number of other research analysts have also recently weighed in on TDOC. Evercore cut their price objective on shares of Teladoc Health from $9.00 to $8.00 and set an “in-line” rating on the stock in a research report on Thursday, October 30th. Piper Sandler reiterated an “overweight” rating and set a $9.00 price target (down from $12.00) on shares of Teladoc Health in a report on Thursday. BMO Capital Markets initiated coverage on shares of Teladoc Health in a research note on Thursday, November 13th. They issued a “market perform” rating and a $8.00 price objective for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Teladoc Health in a research report on Monday, December 29th. Finally, Stifel Nicolaus reduced their price target on Teladoc Health from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Thursday. Four research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $7.80.

Teladoc Health Trading Up 15.1%

Shares of NYSE TDOC opened at $5.35 on Thursday. Teladoc Health has a 1-year low of $4.40 and a 1-year high of $10.02. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.70 and a quick ratio of 2.60. The business’s 50 day moving average is $6.03 and its two-hundred day moving average is $7.21. The stock has a market capitalization of $949.46 million, a P/E ratio of -4.69 and a beta of 2.12.

Teladoc Health (NYSE:TDOC) last announced its earnings results on Wednesday, February 25th. The health services provider reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. The firm had revenue of $642.27 million during the quarter, compared to analysts’ expectations of $635.33 million. Teladoc Health had a negative return on equity of 9.09% and a negative net margin of 7.92%.The company’s quarterly revenue was up .3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.28) EPS. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. As a group, research analysts expect that Teladoc Health will post -1.16 EPS for the current year.

Insider Transactions at Teladoc Health

In other news, insider Carlos Nueno sold 3,897 shares of the stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $7.49, for a total transaction of $29,188.53. Following the transaction, the insider owned 27,175 shares of the company’s stock, valued at approximately $203,540.75. This represents a 12.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Charles Divita III sold 17,138 shares of the firm’s stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $7.63, for a total value of $130,762.94. Following the transaction, the chief executive officer owned 201,036 shares in the company, valued at approximately $1,533,904.68. This represents a 7.86% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 33,288 shares of company stock worth $251,684 in the last ninety days. 0.58% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Teladoc Health by 2.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 193,714 shares of the health services provider’s stock valued at $1,542,000 after purchasing an additional 5,235 shares in the last quarter. NewEdge Advisors LLC raised its stake in Teladoc Health by 1,278.7% in the first quarter. NewEdge Advisors LLC now owns 11,305 shares of the health services provider’s stock worth $90,000 after buying an additional 10,485 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Teladoc Health by 5.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 447,992 shares of the health services provider’s stock worth $3,566,000 after buying an additional 24,124 shares during the period. Acadian Asset Management LLC bought a new stake in Teladoc Health during the 1st quarter valued at $615,000. Finally, AlphaQuest LLC boosted its position in Teladoc Health by 768.2% during the 2nd quarter. AlphaQuest LLC now owns 32,341 shares of the health services provider’s stock valued at $282,000 after acquiring an additional 28,616 shares in the last quarter. 76.82% of the stock is currently owned by institutional investors.

Trending Headlines about Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Q4 beat and narrower loss: Teladoc reported revenue of $642.3M (above estimates) and GAAP loss per share of $0.14 (better than consensus), driven by international growth and strength in Integrated Care; investors view the improved bottom line as a near-term positive. Teladoc Tops Q4 Earnings Estimates on International Growth & Lower Costs
• Positive Sentiment: Selective analyst support: Some firms are staying constructive (Bank of America upgraded to Buy, Piper Sandler reaffirmed Overweight, Canaccord remains a Buy despite lowering its PT), which bolsters demand from buyers who focus on recovery potential. Demystifying Teladoc Health: Insights From 8 Analyst Reviews
• Neutral Sentiment: Midterm growth roadmap: Management projects FY2026 revenue of roughly $2.47B–$2.59B and emphasized investments in AI, insurance relationships and international expansion — initiatives that support longer-term upside but will take time to materialize. Teladoc projects $2.47B–$2.59B revenue in 2026
• Negative Sentiment: Cautious forward guidance: Q1 2026 revenue guidance ($598M–$620M) and EPS guidance (-$0.45 to -$0.35) came in below Wall Street expectations, and FY EPS guidance (-$1.10 to -$0.70) is wider/weaker than consensus — a key reason for mixed investor reactions despite the quarter’s beat. Teladoc Health Reports Fourth Quarter and Full Year 2025 Results
• Negative Sentiment: Analyst price-target cuts: Several firms trimmed price targets (BMO, TD Cowen, Stifel, Wells Fargo, Leerink) and moved to Market Perform/Hold ratings in response to the softer outlook, adding selling pressure for investors focused on nearer-term valuation and earnings visibility. Analyst price-target updates

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.